⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IGC News
IGC Pharma, Inc.
IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome
accessnewswire.com
IGC
IGC
IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada
accessnewswire.com
IGC
IGC
IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City
accessnewswire.com
IGC
IGC
IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1
accessnewswire.com
IGC
IGC
IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression
accessnewswire.com
IGC
IGC
IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial
accessnewswire.com
IGC
IGC